FindTrial
Sign In

Concurrent chemoradiotherapy (cCRT)

DRUG5 trials

Sponsors

Affiliated Hospital of North Sichuan Medical College, Celgene, Sun Yat-sen University, Fudan University

Conditions

Advanced Esophageal Squamous Cell CarcinomaCarcinoma, Non-Small-Cell LungNasopharyngeal Cancinoma (NPC)Nasopharyngeal CarcinomaQuality of LifeUnresectable Esophageal Squamous Cell Carcinoma

Phase 2

Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer
NCT03588494
Affiliated Hospital of North Sichuan Medical CollegeQuality of Life
Start: 2018-08-01End: 2021-09-01Target: 318Updated: 2018-07-17
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
RecruitingNCT06455410
Sun Yat-sen UniversityNasopharyngeal Carcinoma
Start: 2024-06-18End: 2028-06-18Target: 216Updated: 2024-06-25
Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.
Not yet recruitingNCT07469241
Fudan UniversityAdvanced Esophageal Squamous Cell Carcinoma, Unresectable Esophageal Squamous Cell Carcinoma
Start: 2026-03-10End: 2029-06-30Target: 50Updated: 2026-03-13

Phase 3

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer
TerminatedNCT03745222
CelgeneCarcinoma, Non-Small-Cell Lung
Start: 2019-05-22End: 2019-06-26Updated: 2020-07-15
Adaptive Immunotherapy for Nasopharyngeal Carcinoma
RecruitingNCT07154069
Sun Yat-sen UniversityNasopharyngeal Cancinoma (NPC)
Start: 2025-11-13End: 2033-09-30Target: 802Updated: 2025-11-25

Related Papers

Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy.
2020-10-0112 citations
Antibodies to watch in 2020.
2020-01-01328 citations
Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy for newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) in a phase III study (RATIONALE 001).
Journal of Clinical Oncology2019-05-202 citations
RATIONALE 001: Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)
Annals of Oncology2019-04-01